샘플 요청 목록

 카트 문의
시장보고서
상품코드
2017716

무균 주사제 CDMO 시장 규모, 점유율, 동향 분석 보고서 : 분자 유형별, 제품 유형별, 서비스별, 치료 분야별, 투여 경로별, 최종 용도별, 지역별, 부문별 예측(2026-2033년)

Sterile Injectables CDMO Market Size, Share & Trends Analysis Report By Molecule Type, By Product, By Service, By Therapeutic Area, By Route Of Administration, By End-use, By Region, And Segment Forecasts, 2026 - 2033
발행일: | 리서치사: 구분자 Grand View Research | 페이지 정보: 영문 324 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




가격
Unprintable PDF & Excel (Single User License) help
보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.
US $ 5,950 금액 안내 화살표 ￦ 8,854,000
Printable PDF & Excel (5-User License) help
보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.
US $ 6,950 금액 안내 화살표 ￦ 10,342,000
Printable PDF & Excel (Enterprise License) help
PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.
US $ 8,950 금액 안내 화살표 ￦ 13,319,000
카드담기
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

무균 주사제 CDMO 시장 요약

세계의 무균 주사제 CDMO 시장 규모는 2025년에 378억 2,000만 달러로 추정되며, 2033년까지 873억 4,000만 달러에 달할 것으로 예측되며, 2026년부터 2033년까지 CAGR 11.2%로 성장할 것으로 전망됩니다.

이 시장의 성장은 바이오의약품, 바이오시밀러 및 맞춤의료 분야의 의약품 개발 활동 증가, 의약품 승인 프로세스, 치료법의 복잡성 증가, 정밀한 분석적 검증 및 규제 준수에 대한 요구가 증가함에 따라 주도되고 있습니다.

또한, 임상시험 건수의 증가, 제약 및 생명공학 기업들의 전문 CRO(Contract Research Organization)에 대한 연구 활동 아웃소싱 확대, 그리고 지속적인 기술 발전은 시장 성장을 더욱 촉진할 것으로 예상됩니다. 또한, 엄격한 규제 요건, 특히 신흥 시장에서의 연구개발(R&D) 투자 확대, 바이오마커 분석 및 약동학 연구에 대한 관심 증가로 인해 시장 확대가 더욱 가속화될 것으로 예상됩니다.

세포 치료 및 유전자 치료에 대한 수요 증가가 시장 성장을 주도하고 있습니다. 치료제 개발 파이프라인이 확대됨에 따라 위탁생산기관(CMO)이 제공하는 전문 제조 역량에 대한 수요가 증가하고 있습니다. 예를 들어, ClinicalTrials.gov에 따르면, 2024년 3월 현재 북미에서는 다양한 질병을 치료하기 위한 세포 치료 및 관련 접근법에 초점을 맞춘 581개 이상의 임상시험이 진행 중이며, 이는 예측 기간 동안 위탁 생산의 증가를 견인할 것으로 예상됩니다.

바이오시밀러, 바이오의약품, 맞춤의료, 희귀질환 치료제, 동반진단, 적응증별 시험 설계 등의 시장 성장은 무균주사제 CDMO에 대한 수요를 촉진할 것으로 예상됩니다. 이러한 급증은 바이오의약품에 대한 높은 수요, 복잡한 제조 요건 및 규제 대응 지원으로 인해 전문 CDMO에 대한 아웃소싱을 필요로 하는 바이오의약품에 대한 수요가 급증하고 있습니다. 이들 조직은 제약사가 비용을 절감하고 시장 출시 시간을 단축하는 데 필요한 전문 지식, 인프라 및 확장 가능한 제조 솔루션을 제공합니다. 또한, 많은 기업들이 새로운 길을 모색하고 있으며, 규제 준수에 대한 요구가 높아짐에 따라 무균 주사제 위탁 개발 및 제조 업무에 정통한 전문 서비스 제공업체에 대한 수요가 증가하고 있습니다.

또한, 이 부문의 기업들이 시행하는 주요 이니셔티브도 시장 성장을 촉진할 것으로 예상됩니다. 예를 들어, 2025년 10월, 무균 주사제 제조 전문 CDMO인 Simtra BioPharma Solutions는 복잡한 고부가가치 치료법에 대한 세계 수요 증가에 대응하기 위해 2개 대륙에 걸친 확장 계획을 추진하고 있습니다. 2023년 독립 조직으로 전환한 후, 회사는 북미와 유럽 전역에 대한 투자를 강화하고, 생산 기지를 확장하고, 첨단 역량을 확대하고 있습니다. 이 전략적 성장 이니셔티브는 생산능력 향상, 고객 파이프라인 지원 및 주요 제약 시장 전반에 걸쳐 확장 가능한 고품질 무균 솔루션을 제공하기 위한 심트라의 노력을 강조하는 것입니다.

전 세계 알츠하이머병 환자 수의 급증, 첨단 유전자 치료에 대한 수요 증가, 신경 퇴행성 질환의 발생률 증가, 유전성 질환의 증가가 복합적으로 작용하여 첨단 치료법의 확장을 촉진하고 있습니다. 많은 대기업과 중소기업이 기술 및 제조 능력 측면에서 이 분야의 혁신을 주도하고 있으며, 이는 시장 확대를 위한 비즈니스 기회를 창출하고 있습니다. 또한, 최근 이 시장에서의 신제품 승인으로 인해 이 시장에서의 연구개발 활동이 더욱 가속화되고 있습니다.

자주 묻는 질문

  • 무균 주사제 CDMO 시장 규모는 어떻게 예측되나요?
  • 무균 주사제 CDMO 시장 성장은 어떤 요인에 의해 주도되나요?
  • 세포 치료 및 유전자 치료에 대한 수요는 무균 주사제 CDMO 시장에 어떤 영향을 미치나요?
  • 무균 주사제 CDMO에 대한 수요를 촉진하는 시장 성장 요소는 무엇인가요?
  • 무균 주사제 CDMO 시장에서 주요 기업의 이니셔티브는 무엇인가요?

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 무균 주사제 CDMO 시장 : 변수, 동향, 범위

제4장 무균 주사제 CDMO 시장 : 분자 유형별, 추정·동향 분석

제5장 무균 주사제 CDMO 시장 : 제품별, 추정·동향 분석

제6장 무균 주사제 CDMO 시장 : 서비스별, 추정·동향 분석

제7장 무균 주사제 CDMO 시장 : 치료 분야별, 추정·동향 분석

제8장 무균 주사제 CDMO 시장 : 투여 경로별, 추정·동향 분석

제9장 무균 주사제 CDMO 시장 : 최종 용도별, 추정·동향 분석

제10장 무균 주사제 CDMO 시장 : 지역별, 추정·동향 분석

제11장 경쟁 구도

KSM

Sterile Injectables CDMO Market Summary

The global sterile injectables CDMO market size was estimated at USD 37.82 billion in 2025 and is projected to reach USD 87.34 billion by 2033, growing at a CAGR of 11.2% from 2026 to 2033. The market growth is driven by increasing drug development activities of biologics, biosimilars, and personalized medicines, drug approval processes, increasing complexity of therapeutics, and rising need for precise analytical validation and regulatory compliance.

In addition, the increasing number of clinical trials, rising outsourcing of research activities by pharmaceutical and biotechnology companies to specialized contract research organizations (CROs), and ongoing technological advancements are further anticipated to fuel market growth. Furthermore, stringent regulatory requirements, expanding R&D investments, particularly in the emerging markets, and the growing emphasis on biomarker analysis and pharmacokinetic studies are expected to further accelerate market expansion.

The increasing demand for cellular and genetic therapies is driving the market's growth. With the expansion of therapy pipelines, there is a rising requirement for specialized manufacturing capabilities provided by contract manufacturing organizations (CMOs). For instance, according to ClinicalTrials.gov, as of March 2024, over 581 clinical trials were focused on cell therapies and related approaches for treating various diseases in North America is anticipated to drive an increase in contract manufacturing throughout the projected period.

Growth in markets of biosimilars, biologics, personalized medicine, orphan drugs, companion diagnostics, and adaptive trial designs, among others, is anticipated to boost the demand for sterile injectables CDMO. This surge is fueled by the high demand for biologics, complex manufacturing requirements, and regulatory support, which necessitate outsourcing to specialized CDMOs. These organizations provide the required expertise, infrastructure, and scalable manufacturing solutions that pharmaceutical companies need to reduce costs and accelerate time-to-market. Moreover, several companies are investigating new avenues, and the growing requirement to adhere to regulations is driving the demand for specialized service providers with proficiency in sterile injectables contract development and manufacturing affairs.

Furthermore, key initiatives undertaken by the companies in this sector are also expected to boost the market's growth. For instance, in October 2025, Simtra BioPharma Solutions, a specialized CDMO focused on sterile injectable manufacturing, is advancing a two-continent expansion plan aimed at addressing rising global demand for complex, high-value therapies. Following its transition to an independent organization in 2023, the company has intensified investments across North America and Europe, strengthening its manufacturing footprint and expanding advanced capabilities. This strategic growth initiative underscores Simtra's commitment to enhancing capacity, supporting customer pipelines, and delivering scalable, high-quality sterile solutions across key pharmaceutical markets.

The surge in global Alzheimer's disease cases, rising demand for cutting-edge gene therapies, a growing incidence of neurodegenerative diseases, and an increase in genetic disorders collectively propel the expansion of advanced therapies. A substantial number of major and small biotechnology companies are driving innovation in this field in terms of technology and manufacturing capabilities, thereby offering commercial opportunities for market expansion. Furthermore, the recent approval of new products in this market has further accelerated R&D activities in this marketplace.

Global Sterile Injectables CDMO Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global sterile injectables CDMO market report based on molecule type, product, service, therapeutic area, route of administration, end-use, and region.

  • Molecule Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Small Molecule
  • Large Molecule
  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • API
  • Finished Drug Product
    • Pre-filled Syringes
    • Vials and Ampoules
    • Specialty Injectables
    • Others
  • Service Outlook (Revenue, USD Million, 2021 - 2033)
  • Formulation Development
  • Analytical & Testing Services
    • Method Development & Validation
    • Stability Testing
    • Drug Substance
    • Stability Indicating Method Validation
    • Accelerated Stability Testing
    • Photostability Testing
    • Other Stability Testing Methods
    • Extractable & Leachable Testing
    • Others
  • Manufacturing
    • Clinical Trial Manufacturing
    • Commercial Manufacturing
    • Aseptic Fill-Finish Services
  • Packaging
  • Storage
    • Cold
    • Non-cold
  • Others
  • Therapeutic Area Outlook (Revenue, USD Million, 2021 - 2033)
  • Oncology
  • Cardiovascular Diseases
  • Central Nervous System Diseases
  • Infectious Disorders
  • Musculoskeletal Diseases
  • Hormonal Diseases
  • Others
  • Route of Administration Outlook (Revenue, USD Million, 2021 - 2033)
  • Subcutaneous (SC)
  • Intravenous (IV)
  • Intramuscular (IM)
  • Others
  • End-use Outlook (Revenue, USD Million, 2021 - 2033)
  • Pharmaceutical Companies
  • Biopharmaceutical Companies
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
    • Switzerland
    • Ireland
    • Poland
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
    • Colombia
    • Chile
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait
    • Oman
    • Qatar
    • Turkey

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Regional Scope
    • 1.1.2. Estimates and Forecast Timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased Database
    • 1.3.2. GVR's Internal Database
    • 1.3.3. Secondary Sources
    • 1.3.4. Primary Research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data Analysis Models
  • 1.5. Market Formulation & Validation
    • 1.5.1. Region Wise Market: Base Estimates
    • 1.5.2. Global Market: CAGR Calculation
  • 1.6. Model Details
    • 1.6.1. Commodity Flow Analysis (Model 1)
    • 1.6.2. Value-Chain-Based Sizing & Forecasting (Model 2)
    • 1.6.3. QFD Model Sizing & Forecasting (Model 3)
    • 1.6.4. Bottom-Up Approach (Model 4)
  • 1.7. Market Definitions
  • 1.8. List of Secondary Sources
  • 1.9. List of Abbreviations
  • 1.10. Objectives
    • 1.10.1. Objective - 1:
    • 1.10.2. Objective - 2:
    • 1.10.3. Objective - 3:
    • 1.10.4. Objective - 4:

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Molecule Type Outlook
    • 2.2.2. Product Outlook
    • 2.2.3. Service Outlook
    • 2.2.4. Therapeutic Area Outlook
    • 2.2.5. Route of Administration Outlook
    • 2.2.6. End Use Outlook
    • 2.2.7. Regional Outlook
  • 2.3. Competitive Insights

Chapter 3. Sterile Injectables CDMO Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing Pipeline and Approvals of Injectables
      • 3.2.1.2. Growing Demand for Biologics and Biosimilars Significantly Supported Market Growth
      • 3.2.1.3. Rise in Investment Across Research & Development Activities for the Development of Novel Therapeutics
      • 3.2.1.4. Increasing Demand for Cell & Gene Therapies
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Low Barriers to Market Penetration Have Resulted in Pricing Pressure
      • 3.2.2.2. Challenges Related to Quality Control
  • 3.3. Technological Advancements
  • 3.4. Pricing Model Analysis
  • 3.5. Clinical Trials Volume Analysis, 2023
    • 3.5.1. Total Number of Clinical Trials, by Region (2023)
    • 3.5.2. Total Number of Clinical Trials, by Phase (2023)
    • 3.5.3. Total Number of Clinical Trials, by Study Design (2023)
    • 3.5.4. Total Number of Clinical Trials, by Key Therapeutic Area (2023)
  • 3.6. Sterile Injectables CDMO Market: Analysis Tools
    • 3.6.1. Porter's Five Forces Analysis
    • 3.6.2. PESTEL Analysis
  • 3.7. COVID-19 Impact Analysis

Chapter 4. Sterile Injectables CDMO Market: Molecule Type Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Sterile Injectables CDMO Market Movement Analysis
  • 4.3. Global Sterile Injectables CDMO Market Size & Trend Analysis, by Molecule Type, 2021 to 2033 (USD Million)
  • 4.4. Small Molecule
    • 4.4.1. Market Estimates and Forecast, 2021 to 2033 (USD Million)
  • 4.5. Large Molecule
    • 4.5.1. Market Estimates and Forecast, 2021 to 2033 (USD Million)

Chapter 5. Sterile Injectables CDMO Market: Product Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Sterile Injectables CDMO Market Movement Analysis
  • 5.3. Global Sterile Injectables CDMO Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
  • 5.4. API
    • 5.4.1. Market Estimates and Forecast, 2021 to 2033 (USD Million)
  • 5.5. Finished Drug Product
    • 5.5.1. Market Estimates and Forecast, 2021 to 2033 (USD Million)
    • 5.5.2. Pre-filled Syringes
      • 5.5.2.1. Market Estimates and Forecast, 2021 to 2033 (USD Million)
    • 5.5.3. Vials and Ampoules
      • 5.5.3.1. Market Estimates and Forecast, 2021 to 2033 (USD Million)
    • 5.5.4. Specialty Injectables
      • 5.5.4.1. Market Estimates and Forecast, 2021 to 2033 (USD Million)
    • 5.5.5. Others
      • 5.5.5.1. Market Estimates and Forecast, 2021 to 2033 (USD Million)

Chapter 6. Sterile Injectables CDMO Market: Service Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Sterile Injectables CDMO Market Movement Analysis
  • 6.3. Global Sterile Injectables CDMO Market Size & Trend Analysis, by Service, 2021 to 2033 (USD Million)
  • 6.4. Formulation Development
    • 6.4.1. Market Estimates and Forecast, 2021 to 2033 (USD Million)
  • 6.5. Analytical and Testing Services
    • 6.5.1. Market Estimates and Forecast, 2021 to 2033 (USD Million)
    • 6.5.2. Method Development and Validation
      • 6.5.2.1. Market Estimates and Forecast, 2021 to 2033 (USD Million)
    • 6.5.3. Stability Testing
      • 6.5.3.1. Market Estimates and Forecast, 2021 to 2033 (USD Million)
      • 6.5.3.2. Drug Substance
        • 6.5.3.2.1. Market Estimates and Forecast, 2021 to 2033 (USD Million)
      • 6.5.3.3. Stability Indicating Method Validation
        • 6.5.3.3.1. Market Estimates and Forecast, 2021 to 2033 (USD Million)
      • 6.5.3.4. Accelerated Stability Testing
        • 6.5.3.4.1. Market Estimates and Forecast, 2021 to 2033 (USD Million)
      • 6.5.3.5. Photostability Testing
        • 6.5.3.5.1. Market Estimates and Forecast, 2021 to 2033 (USD Million)
      • 6.5.3.6. Other Stability Testing Methods
        • 6.5.3.6.1. Market Estimates and Forecast, 2021 to 2033 (USD Million)
    • 6.5.4. Extractable & Leachable Testing
      • 6.5.4.1. Market Estimates and Forecast, 2021 to 2033 (USD Million)
    • 6.5.5. Others
      • 6.5.5.1. Market Estimates and Forecast, 2021 to 2033 (USD Million)
  • 6.6. Manufacturing
    • 6.6.1. Market Estimates and Forecast, 2021 to 2033 (USD Million)
    • 6.6.2. Clinical Trial Manufacturing
      • 6.6.2.1. Market Estimates and Forecast, 2021 to 2033 (USD Million)
    • 6.6.3. Commercial Manufacturing
      • 6.6.3.1. Market Estimates and Forecast, 2021 to 2033 (USD Million)
    • 6.6.4. Aseptic Fill-Finish Services
      • 6.6.4.1. Market Estimates and Forecast, 2021 to 2033 (USD Million)
  • 6.7. Packaging
    • 6.7.1. Market Estimates and Forecast, 2021 to 2033 (USD Million)
  • 6.8. Storage
    • 6.8.1. Market Estimates and Forecast, 2021 to 2033 (USD Million)
    • 6.8.2. Cold
      • 6.8.2.1. Market Estimates and Forecast, 2021 to 2033 (USD Million)
    • 6.8.3. Non-cold
      • 6.8.3.1. Market Estimates and Forecast, 2021 to 2033 (USD Million)
  • 6.9. Others
    • 6.9.1. Market Estimates and Forecast, 2021 to 2033 (USD Million)

Chapter 7. Sterile Injectables CDMO Market: Therapeutic Area Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Global Sterile Injectables CDMO Market Movement Analysis
  • 7.3. Global Sterile Injectables CDMO Market Size & Trend Analysis, by Therapeutic Area, 2021 to 2033 (USD Million)
  • 7.4. Oncology
    • 7.4.1. Market Estimates and Forecast, 2021 to 2033 (USD Million)
  • 7.5. Cardiovascular Diseases
    • 7.5.1. Market Estimates and Forecast, 2021 to 2033 (USD Million)
  • 7.6. Central Nervous System Diseases
    • 7.6.1. Market Estimates and Forecast, 2021 to 2033 (USD Million)
  • 7.7. Infectious Disorders
    • 7.7.1. Market Estimates and Forecast, 2021 to 2033 (USD Million)
  • 7.8. Musculoskeletal Diseases
    • 7.8.1. Market Estimates and Forecast, 2021 to 2033 (USD Million)
  • 7.9. Hormonal Diseases
    • 7.9.1. Market Estimates and Forecast, 2021 to 2033 (USD Million)
  • 7.10. Others
    • 7.10.1. Market Estimates and Forecast, 2021 to 2033 (USD Million)

Chapter 8. Sterile Injectables CDMO Market: Route of Administration Estimates & Trend Analysis

  • 8.1. Segment Dashboard
  • 8.2. Global Sterile Injectables CDMO Market Movement Analysis
  • 8.3. Global Sterile Injectables CDMO Market Size & Trend Analysis, by Route of Administration, 2021 to 2033 (USD Million)
  • 8.4. Subcutaneous (SC)
    • 8.4.1. Market Estimates and Forecast, 2021 to 2033 (USD Million)
  • 8.5. Intravenous (IV)
    • 8.5.1. Market Estimates and Forecast, 2021 to 2033 (USD Million)
  • 8.6. Intramuscular (IM)
    • 8.6.1. Market Estimates and Forecast, 2021 to 2033 (USD Million)
  • 8.7. Others
    • 8.7.1. Market Estimates and Forecast, 2021 to 2033 (USD Million)

Chapter 9. Sterile Injectables CDMO Market: End Use Estimates & Trend Analysis

  • 9.1. Segment Dashboard
  • 9.2. Global Sterile Injectables CDMO Market Movement Analysis
  • 9.3. Global Sterile Injectables CDMO Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
  • 9.4. Pharmaceutical Companies
    • 9.4.1. Market Estimates and Forecast, 2021 to 2033 (USD Million)
  • 9.5. Biopharmaceutical Companies
    • 9.5.1. Market Estimates and Forecast, 2021 to 2033 (USD Million)
  • 9.6. Others
    • 9.6.1. Market Estimates and Forecast, 2021 to 2033 (USD Million)

Chapter 10. Sterile Injectables CDMO Market: Regional Estimates & Trend Analysis

  • 10.1. Regional Market Share Analysis, 2025 & 2033
  • 10.2. Regional Market Dashboard
  • 10.3. Global Regional Market Snapshot
  • 10.4. North America
    • 10.4.1. North America Market Estimates and Forecast, 2021 to 2033 (USD Million)
    • 10.4.2. U.S.
      • 10.4.2.1. Key Country Dynamics
      • 10.4.2.2. Competitive Scenario
      • 10.4.2.3. Regulatory Scenario
      • 10.4.2.4. Market Estimates and Forecast, 2021 to 2033 (USD Million)
    • 10.4.3. Canada
      • 10.4.3.1. Key Country Dynamics
      • 10.4.3.2. Competitive Scenario
      • 10.4.3.3. Regulatory Scenario
      • 10.4.3.4. Market Estimates and Forecast, 2021 to 2033 (USD Million)
    • 10.4.4. Mexico
      • 10.4.4.1. Key Country Dynamics
      • 10.4.4.2. Competitive Scenario
      • 10.4.4.3. Regulatory Scenario
      • 10.4.4.4. Market Estimates and Forecast, 2021 to 2033 (USD Million)
  • 10.5. Europe
    • 10.5.1. Europe Market Estimates and Forecast, 2021 to 2033 (USD Million)
    • 10.5.2. UK
      • 10.5.2.1. Key Country Dynamics
      • 10.5.2.2. Competitive Scenario
      • 10.5.2.3. Regulatory Scenario
      • 10.5.2.4. Market Estimates and Forecast, 2021 to 2033 (USD Million)
    • 10.5.3. Germany
      • 10.5.3.1. Key Country Dynamics
      • 10.5.3.2. Competitive Scenario
      • 10.5.3.3. Regulatory Scenario
      • 10.5.3.4. Market Estimates and Forecast, 2021 to 2033 (USD Million)
    • 10.5.4. France
      • 10.5.4.1. Key Country Dynamics
      • 10.5.4.2. Competitive Scenario
      • 10.5.4.3. Regulatory Scenario
      • 10.5.4.4. Market Estimates and Forecast, 2021 to 2033 (USD Million)
    • 10.5.5. Italy
      • 10.5.5.1. Key Country Dynamics
      • 10.5.5.2. Competitive Scenario
      • 10.5.5.3. Regulatory Scenario
      • 10.5.5.4. Market Estimates and Forecast, 2021 to 2033 (USD Million)
    • 10.5.6. Spain
      • 10.5.6.1. Key Country Dynamics
      • 10.5.6.2. Competitive Scenario
      • 10.5.6.3. Regulatory Scenario
      • 10.5.6.4. Market Estimates and Forecast, 2021 to 2033 (USD Million)
    • 10.5.7. Denmark
      • 10.5.7.1. Key Country Dynamics
      • 10.5.7.2. Competitive Scenario
      • 10.5.7.3. Regulatory Scenario
      • 10.5.7.4. Market Estimates and Forecast, 2021 to 2033 (USD Million)
    • 10.5.8. Sweden
      • 10.5.8.1. Key Country Dynamics
      • 10.5.8.2. Competitive Scenario
      • 10.5.8.3. Regulatory Scenario
      • 10.5.8.4. Market Estimates and Forecast, 2021 to 2033 (USD Million)
    • 10.5.9. Norway
      • 10.5.9.1. Key Country Dynamics
      • 10.5.9.2. Competitive Scenario
      • 10.5.9.3. Regulatory Scenario
      • 10.5.9.4. Market Estimates and Forecast, 2021 to 2033 (USD Million)
    • 10.5.10. Switzerland
      • 10.5.10.1. Key Country Dynamics
      • 10.5.10.2. Competitive Scenario
      • 10.5.10.3. Regulatory Scenario
      • 10.5.10.4. Market Estimates and Forecast, 2021 to 2033 (USD Million)
    • 10.5.11. Ireland
      • 10.5.11.1. Key Country Dynamics
      • 10.5.11.2. Competitive Scenario
      • 10.5.11.3. Regulatory Scenario
      • 10.5.11.4. Market Estimates and Forecast, 2021 to 2033 (USD Million)
    • 10.5.12. Poland
      • 10.5.12.1. Key Country Dynamics
      • 10.5.12.2. Competitive Scenario
      • 10.5.12.3. Regulatory Scenario
      • 10.5.12.4. Market Estimates and Forecast, 2021 to 2033 (USD Million)
  • 10.6. Asia Pacific
    • 10.6.1. Asia Pacific Market Estimates and Forecast, 2021 to 2033 (USD Million)
    • 10.6.2. Japan
      • 10.6.2.1. Key Country Dynamics
      • 10.6.2.2. Competitive Scenario
      • 10.6.2.3. Regulatory Scenario
      • 10.6.2.4. Market Estimates and Forecast, 2021 to 2033 (USD Million)
    • 10.6.3. China
      • 10.6.3.1. Key Country Dynamics
      • 10.6.3.2. Competitive Scenario
      • 10.6.3.3. Regulatory Scenario
      • 10.6.3.4. Market Estimates and Forecast, 2021 to 2033 (USD Million)
    • 10.6.4. India
      • 10.6.4.1. Key Country Dynamics
      • 10.6.4.2. Competitive Scenario
      • 10.6.4.3. Regulatory Scenario
      • 10.6.4.4. Market Estimates and Forecast, 2021 to 2033 (USD Million)
    • 10.6.5. South Korea
      • 10.6.5.1. Key Country Dynamics
      • 10.6.5.2. Competitive Scenario
      • 10.6.5.3. Regulatory Scenario
      • 10.6.5.4. Market Estimates and Forecast, 2021 to 2033 (USD Million)
    • 10.6.6. Australia
      • 10.6.6.1. Key Country Dynamics
      • 10.6.6.2. Competitive Scenario
      • 10.6.6.3. Regulatory Scenario
      • 10.6.6.4. Market Estimates and Forecast, 2021 to 2033 (USD Million)
    • 10.6.7. Thailand
      • 10.6.7.1. Key Country Dynamics
      • 10.6.7.2. Competitive Scenario
      • 10.6.7.3. Regulatory Scenario
      • 10.6.7.4. Market Estimates and Forecast, 2021 to 2033 (USD Million)
  • 10.7. Latin America
    • 10.7.1. Latin America Market Estimates and Forecast, 2021 to 2033 (USD Million)
    • 10.7.2. Brazil
      • 10.7.2.1. Key Country Dynamics
      • 10.7.2.2. Competitive Scenario
      • 10.7.2.3. Regulatory Scenario
      • 10.7.2.4. Market Estimates and Forecast, 2021 to 2033 (USD Million)
    • 10.7.3. Argentina
      • 10.7.3.1. Key Country Dynamics
      • 10.7.3.2. Competitive Scenario
      • 10.7.3.3. Regulatory Scenario
      • 10.7.3.4. Market Estimates and Forecast, 2021 to 2033 (USD Million)
    • 10.7.4. Colombia
      • 10.7.4.1. Key Country Dynamics
      • 10.7.4.2. Competitive Scenario
      • 10.7.4.3. Regulatory Scenario
      • 10.7.4.4. Market Estimates and Forecast, 2021 to 2033 (USD Million)
    • 10.7.5. Chile
      • 10.7.5.1. Key Country Dynamics
      • 10.7.5.2. Competitive Scenario
      • 10.7.5.3. Regulatory Scenario
      • 10.7.5.4. Market Estimates and Forecast, 2021 to 2033 (USD Million)
  • 10.8. MEA
    • 10.8.1. MEA Market Estimates and Forecast, 2021 to 2033 (USD Million)
    • 10.8.2. South Africa
      • 10.8.2.1. Key Country Dynamics
      • 10.8.2.2. Competitive Scenario
      • 10.8.2.3. Regulatory Scenario
      • 10.8.2.4. Market Estimates and Forecast, 2021 to 2033 (USD Million)
    • 10.8.3. Saudi Arabia
      • 10.8.3.1. Key Country Dynamics
      • 10.8.3.2. Competitive Scenario
      • 10.8.3.3. Regulatory Scenario
      • 10.8.3.4. Market Estimates and Forecast, 2021 to 2033 (USD Million)
    • 10.8.4. UAE
      • 10.8.4.1. Key Country Dynamics
      • 10.8.4.2. Competitive Scenario
      • 10.8.4.3. Regulatory Scenario
      • 10.8.4.4. Market Estimates and Forecast, 2021 to 2033 (USD Million)
    • 10.8.5. Kuwait
      • 10.8.5.1. Key Country Dynamics
      • 10.8.5.2. Competitive Scenario
      • 10.8.5.3. Regulatory Scenario
      • 10.8.5.4. Market Estimates and Forecast, 2021 to 2033 (USD Million)
    • 10.8.6. Oman
      • 10.8.6.1. Key Country Dynamics
      • 10.8.6.2. Competitive Scenario
      • 10.8.6.3. Regulatory Scenario
      • 10.8.6.4. Market Estimates and Forecast, 2021 to 2033 (USD Million)
    • 10.8.7. Qatar
      • 10.8.7.1. Key Country Dynamics
      • 10.8.7.2. Competitive Scenario
      • 10.8.7.3. Regulatory Scenario
      • 10.8.7.4. Market Estimates and Forecast, 2021 to 2033 (USD Million)
    • 10.8.8. Turkey
      • 10.8.8.1. Key Country Dynamics
      • 10.8.8.2. Competitive Scenario
      • 10.8.8.3. Regulatory Scenario
      • 10.8.8.4. Market Estimates and Forecast, 2021 to 2033 (USD Million)

Chapter 11. Competitive Landscape

  • 11.1. Market Participant Categorization
    • 11.1.1. Market Leaders
    • 11.1.2. Emerging Players
  • 11.2. Market Assessment Analysis, 2025 (Heat Map Analysis)
  • 11.3. Company Profiles
    • 11.3.1. Boehringer Ingelheim GmbH
      • 11.3.1.1. Company Overview
      • 11.3.1.2. Financial Performance
      • 11.3.1.3. Service Benchmarking
      • 11.3.1.4. Strategic Initiatives
    • 11.3.2. Boehringer Ingelheim GmbH
      • 11.3.2.1. Company Overview
      • 11.3.2.2. Financial Performance
      • 11.3.2.3. Service Benchmarking
      • 11.3.2.4. Strategic Initiatives
    • 11.3.3. Vetter Pharma
      • 11.3.3.1. Company Overview
      • 11.3.3.2. Financial Performance
      • 11.3.3.3. Service Benchmarking
      • 11.3.3.4. Strategic Initiatives
    • 11.3.4. Recipharm AB
      • 11.3.4.1. Company Overview
      • 11.3.4.2. Financial Performance
      • 11.3.4.3. Service Benchmarking
      • 11.3.4.4. Strategic Initiatives
    • 11.3.5. Aenova Group
      • 11.3.5.1. Company Overview
      • 11.3.5.2. Financial Performance
      • 11.3.5.3. Service Benchmarking
      • 11.3.5.4. Strategic Initiatives
    • 11.3.6. Fresenius Kabi
      • 11.3.6.1. Company Overview
      • 11.3.6.2. Financial Performance
      • 11.3.6.3. Service Benchmarking
      • 11.3.6.4. Strategic Initiatives
    • 11.3.7. Famar
      • 11.3.7.1. Company Overview
      • 11.3.7.2. Financial Performance
      • 11.3.7.3. Service Benchmarking
      • 11.3.7.4. Strategic Initiatives
    • 11.3.8. NextPharma Technologies
      • 11.3.8.1. Company Overview
      • 11.3.8.2. Financial Performance
      • 11.3.8.3. Service Benchmarking
      • 11.3.8.4. Strategic Initiatives
    • 11.3.9. Ajinomoto Bio-Pharma Services
      • 11.3.9.1. Company Overview
      • 11.3.9.2. Financial Performance
      • 11.3.9.3. Service Benchmarking
      • 11.3.9.4. Strategic Initiatives
    • 11.3.10. PCI Pharma Services
      • 11.3.10.1. Company Overview
      • 11.3.10.2. Financial Performance
      • 11.3.10.3. Service Benchmarking
      • 11.3.10.4. Strategic Initiatives
    • 11.3.11. IDT Biologika
      • 11.3.11.1. Company Overview
      • 11.3.11.2. Financial Performance
      • 11.3.11.3. Service Benchmarking
      • 11.3.11.4. Strategic Initiatives
    • 11.3.12. Alcami Corporation
      • 11.3.12.1. Company Overview
      • 11.3.12.2. Financial Performance
      • 11.3.12.3. Service Benchmarking
      • 11.3.12.4. Strategic Initiatives
    • 11.3.13. Fareva Group
      • 11.3.13.1. Company Overview
      • 11.3.13.2. Financial Performance
      • 11.3.13.3. Service Benchmarking
      • 11.3.13.4. Strategic Initiatives
    • 11.3.14. Eurofins CDMO
      • 11.3.14.1. Company Overview
      • 11.3.14.2. Financial Performance
      • 11.3.14.3. Service Benchmarking
      • 11.3.14.4. Strategic Initiatives
    • 11.3.15. Siegfried Holding AG
      • 11.3.15.1. Company Overview
      • 11.3.15.2. Financial Performance
      • 11.3.15.3. Service Benchmarking
      • 11.3.15.4. Strategic Initiatives
×

원하시는 정보를 찾아 드릴까요?

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제
문의
원하시는 정보를
찾아 드릴까요?
문의주시면 필요한 정보를
신속하게 찾아드릴게요.
02-2025-2992
kr-info@giikorea.co.kr
문의하기